

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb40483</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Pitfalls of Restriction Enzyme Mapping Following Generation of CRISPR Constructs</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Hassani</surname><given-names>Mehdi</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hesami</surname><given-names>Sara</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Maroofi</surname><given-names>Nahal</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Banan</surname><given-names>Mehdi</given-names></name></contrib><aff>National Institute of Genetic Engineering and Biotechnology (NIGEB), Shahrak-e Pajoohesh, Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>13</volume>
      <issue>4</issue>
      <fpage>226</fpage>
      <lpage>229</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>2</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>4</month>
          <year>2021</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Background:&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;The PX330 and the related PX459 plasmids are widely used for Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9-mediated genome editing. Screening for plasmids containing the correct sgRNA template insertion is one of the most important steps in this system. Different methods for screening the sgRNA inserts have been deployed. One such method is Restriction Enzyme (RE) mapping.&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;Restriction enzyme mapping can be used to screen for numerous plasmid recombinants simultaneously.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Methods:&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;In this study, the sgRNA templates were initially cloned into the above PX459 plasmids. Subsequently, the accuracy of the constructs was determined by RE mapping.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Results:&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;This method was established to screen for sgRNA-bearing PX459 plasmids. However, numerous anomalies were detected after ligation of sgRNA templates into RE digested PX459 plasmids.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Conclusion:&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;Our data suggest that RE mapping is only appropriate as an initial screen and that the identity of all plasmids with the correctly identified RE maps should be confirmed by Sanger sequencing. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
